AI & Imaging
AIRS Medical SwiftMR gains FDA clearance for OEM MRI pipelines
SwiftMR can now operate with OEM deep-learning reconstruction pipelines to add scan-time reduction or extend AI image enhancement to more MRI sequences.
Section
All News
Every story we've published, newest first. 296 articles.
Business
ScreenPoint puts $16M toward Transpara breast AI expansion
The funding will support product development and international expansion of ScreenPoint Medical’s Transpara breast AI solutions.
AI & Imaging
FDA clears Philips Verida spectral CT system for U.S. use
The AI-powered spectral CT system uses a third-generation dual-layer detector and deep-learning reconstruction engine.
AI & Imaging
Lunit DBT update adds prior-exam comparison for breast AI
Version 1.2 of Lunit INSIGHT DBT adds current-prior comparison, selectable operating thresholds, and access to Volpara Scorecard density measures.
Business
Canada adds Vueway to macrocyclic MRI contrast options
The approval covers Vueway injection, a macrocyclic gadolinium-based contrast agent for contrast-enhanced MRI in adults and children 2 years and older.
Practice
Aetna fraud suit against Radiology Partners dismissed in Florida
The Middle District of Florida dismissed Aetna’s lawsuit over No Surprises Act IDR awards involving Radiology Partners and Mori, Bean and Brooks.
Business
Siemens sets 2027 vote for Healthineers spin-off
Siemens plans to put the direct spin-off of Siemens Healthineers shares to a shareholder vote at its February 2027 Annual General Meeting.
Practice
FDA pushes sponsors to report missing trial results
The agency contacted more than 2,200 companies and researchers tied to more than 3,000 registered clinical trials that may be missing required results submissions.
AI & Imaging
Bunkerhill wins FDA clearance for calcium AI on contrast chest CT
Bunkerhill Contrast CAC and Bunkerhill Contrast AVC detect and quantify coronary artery calcium and aortic valve calcium on non-gated, contrast-enhanced chest CT scans.
Clinical
Telix phase 3 trial tests radiopharmaceutical therapy for recurrent glioblastoma
The IPAX BrIGHT trial is evaluating TLX101-Tx with lomustine versus lomustine alone in patients with recurrent glioblastoma.